Drug Profile

AUG 3387

Alternative Names: AUG-3387

Latest Information Update: 29 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Augmenta Bioworks; TFF Pharmaceuticals
Class Antivirals; Monoclonal antibodies
Mechanism of Action Virus internalisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued COVID 2019 infections

Most Recent Events

03 Mar 2025 Discontinued - Preclinical for COVID-2019 infections (Prevention) in USA (Inhalation)
03 Mar 2025 Discontinued - Preclinical for COVID-2019 infections in USA (Inhalation)
28 Mar 2024 TFF Pharmaceuticals and Augmenta Bioworks suspends the collaboration agreement for the development of monoclonal antibodies worldwide for COVID-2019 infections

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com